IDEAYA Biosciences Inc IDYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
-
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
-
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
-
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $38.42
- Day Range
- $37.62–39.32
- 52-Week Range
- $26.05–42.68
- Bid/Ask
- $36.75 / $40.85
- Shares Outstanding
- 96.49M
- Market Cap
- $3.65B
- Volume/Avg
- 712,274 / 846,401
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.45
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 145
- Website
- https://www.ideayabio.com
Valuation
|
Metric
|
IDYA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.04 |
Price/Sales | 14.45 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IDYA
|
|---|---|
Quick Ratio | 10.21 |
Current Ratio | 10.45 |
Interest Coverage | — |
Quick Ratio
IDYA
Profitability
|
Metric
|
IDYA
|
|---|---|
Return on Assets (Normalized) | −10.56% |
Return on Equity (Normalized) | −11.50% |
Return on Invested Capital (Normalized) | −15.12% |
Return on Assets
IDYA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>@k<qn | LOCK|F<^$ | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@&WX<$ | LOCK|%#k@q | $76B | |||
| Moderna Inc
MRNA
| LOCK|X&wt!b^ | LOCK|P$% | $75B | |||
| argenx SE ADR
ARGX
| LOCK|$q?m^J | LOCK|q<@ | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^xC#gM | LOCK|WG | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$!g$b< | LOCK|YR^& | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|VmNyK!? | LOCK|^KcS | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|VQ>%Mr | LOCK|nJ | $24B | |||
| Incyte Corp
INCY
| LOCK|%vn%FX! | LOCK|Wr< | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|l$@!!w& | LOCK|X#$ | $15B |
United States